WHO Grade III Glioma Clinical Trial
Official title:
Metabolic Imaging of Patients With Lower Grade Glioma Using Hyperpolarized 13C Pyruvate
This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.
PRIMARY OBJECTIVES: I. To assess the safety and feasibility of hyperpolarized 13C MR metabolic imaging as a new and unique tool for making an early assessment of progression and evaluation of response to therapy in patients with lower grade glioma II. To determine whether changes in levels of hyperpolarized 13C pyruvate, lactate and bicarbonate may provide early evidence of tumor progression in patients with lower grade glioma who are being followed with surveillance scans. III. To determine whether patients with lower grade glioma who are receiving treatment exhibit a reduction in levels of hyperpolarized 13C lactate/pyruvate at follow-up compared to their baseline scan. OUTLINE: Patients will be enrolled into Cohort 2. Participants previously enrolled in Cohort 1 may enroll in Cohort 2 of study upon re-review of eligibility. COHORT 1 (CLOSED TO ENROLLMENT): Patients undergo MR imaging (MRI) and MR spectroscopic imaging (MRSI) scans over 1 hour at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care. COHORT 2: Patients undergo MRI scan at baseline. Patients then receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than 1 minute and undergo MRSI scan at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06333899 -
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
|
Early Phase 1 | |
| Recruiting |
NCT05009992 -
Combination Therapy for the Treatment of Diffuse Midline Gliomas
|
Phase 2 | |
| Not yet recruiting |
NCT05843253 -
Study of Ribociclib and Everolimus in HGG and DIPG
|
Phase 2 | |
| Not yet recruiting |
NCT05839379 -
Targeted Pediatric High-Grade Glioma Therapy
|
||
| Recruiting |
NCT04479696 -
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
|
N/A | |
| Not yet recruiting |
NCT06161974 -
Study of Olutasidenib and Temozolomide in HGG
|
Phase 2 | |
| Completed |
NCT04630379 -
Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers
|
N/A | |
| Recruiting |
NCT03251027 -
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
|
N/A | |
| Recruiting |
NCT04623931 -
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
|
Phase 2 | |
| Active, not recruiting |
NCT03244995 -
Mind-Body Intervention in Glioma Couples
|
N/A | |
| Active, not recruiting |
NCT03180502 -
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
|
Phase 2 | |
| Active, not recruiting |
NCT03389230 -
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
|
Phase 1 | |
| Recruiting |
NCT03749187 -
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
|
Phase 1 | |
| Active, not recruiting |
NCT01817751 -
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
|
Phase 2 |